NCT01808144View on ClinicalTrials.gov

Lesinurad and Febuxostat Combination Extension Study in Gout

PHASE3CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

August 9, 2016

Study Completion Date

October 6, 2016

Conditions
Gout
Interventions
DRUG

lesinurad

Tablets, 400 mg once daily (QD)

DRUG

lesinurad

Tablets, 200 mg QD

DRUG

febuxostat

Tabletsm 80 mg QD

Trial Locations (72)

1023

Grafton

1705

Fribourg

1708

Fribourg

2050

Camperdown

3143

Tauranga

5011

Woodville South

7000

Hobart

10036

New York

15012

Belle Vernon

15206

Pittsburgh

18960

Sellersville

19446

Lansdale

21702

Frederick

23235

Richmond

23320

Chesapeake

24541

Danville

26505

Morgantown

28401

Wilmington

29204

Columbia

29303

Spartanburg

29464

Mt. Pleasant

30097

Johns Creek

33027

Pembroke Pines

33472

Boynton Beach

33606

Tampa

33614

Tampa

33880

Winter Haven

34102

Naples

35211

Birmingham

38119

Memphis

38654

Olive Branch

39202

Jackson

42701

Elizabethtown

43203

Columbus

44130

Middleburg Heights

44281

Wadsworth

48034

Southfield

48109

Ann Arbor

58103

Fargo

60031

Gurnee

62704

Springfield

63117

St Louis

65109

Jefferson City

73103

Oklahoma City

75218

Dallas

76710

Waco

77074

Houston

77479

Sugar Land

77901

Victoria

78229

San Antonio

78705

Austin

78758

Austin

80113

Englewood

80220

Denver

83646

Meridian

85282

Tempe

91204

Glendale

92108

San Diego

92618

Irvine

92646

Huntington Beach

96814

Honolulu

98104

Seattle

L5M 2V8

Mississauga

M9W4L6

Toronto

60-773

Poznan

99-300

Kutno

30-510

Krakow

31-501

Krakow

15-430

Bialystok

40-954

Katowice

82-300

Elblag

26-200

Gmina Końskie

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT01808144 - Lesinurad and Febuxostat Combination Extension Study in Gout | Biotech Hunter | Biotech Hunter